Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine in elderly patients with Major Depressive Disorder
NCT00811252Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Jan 2009
- Primary completion
- Feb 2010
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Lundbeck. Primary endpoint: Hamilton Depression Rating Scale (24-item) at 8 weeks. Started Jan 2009; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00811252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811252.